ENXTBR:SEQUA

Stock Analysis Report

Executive Summary

Sequana Medical NV, a commercial stage medical device company, focuses on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites, and other fluid imbalance disorders.


Snowflake Analysis

Limited growth with imperfect balance sheet.

Share Price & News

How has Sequana Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SEQUA's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-6.0%

SEQUA

2.9%

BE Medical Equipment

2.3%

BE Market


1 Year Return

-22.9%

SEQUA

4.4%

BE Medical Equipment

-28.9%

BE Market

Return vs Industry: SEQUA underperformed the Belgian Medical Equipment industry which returned 5.4% over the past year.

Return vs Market: SEQUA exceeded the Belgian Market which returned -28.1% over the past year.


Shareholder returns

SEQUAIndustryMarket
7 Day-6.0%2.9%2.3%
30 Day-23.4%-9.6%-17.3%
90 Day-18.7%-10.3%-29.9%
1 Year-22.9%-22.9%5.9%4.4%-27.5%-28.9%
3 Yearn/a43.9%37.6%-33.0%-37.4%
5 Yearn/a85.1%67.2%-35.3%-42.7%

Price Volatility Vs. Market

How volatile is Sequana Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Sequana Medical undervalued compared to its fair value and its price relative to the market?

68.43x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SEQUA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate SEQUA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SEQUA is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: SEQUA is unprofitable, so we can't compare its PE Ratio to the Belgian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SEQUA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SEQUA is overvalued based on its PB Ratio (67.7x) compared to the XE Medical Equipment industry average (3.5x).


Next Steps

Future Growth

How is Sequana Medical forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

33.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SEQUA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SEQUA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SEQUA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SEQUA's revenue (65.7% per year) is forecast to grow faster than the Belgian market (1.7% per year).

High Growth Revenue: SEQUA's revenue (65.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: SEQUA is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Sequana Medical performed over the past 5 years?

-8.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SEQUA is currently unprofitable.

Growing Profit Margin: SEQUA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SEQUA is unprofitable, and losses have increased over the past 5 years at a rate of -8.4% per year.

Accelerating Growth: Unable to compare SEQUA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SEQUA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (3.1%).


Return on Equity

High ROE: SEQUA has a negative Return on Equity (-1617.39%), as it is currently unprofitable.


Next Steps

Financial Health

How is Sequana Medical's financial position?


Financial Position Analysis

Short Term Liabilities: SEQUA's short term assets (€8.5M) exceed its short term liabilities (€5.3M).

Long Term Liabilities: SEQUA's short term assets (€8.5M) exceed its long term liabilities (€3.1M).


Debt to Equity History and Analysis

Debt Level: SEQUA's debt to equity ratio (293.7%) is considered high.

Reducing Debt: Insufficient data to determine if SEQUA's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: SEQUA has a high level of physical assets or inventory.

Debt Coverage by Assets: SEQUA's debt is covered by short term assets (assets are 3.1x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SEQUA has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: SEQUA has less than a year of cash runway if free cash flow continues to reduce at historical rates of -13.2% each year


Next Steps

Dividend

What is Sequana Medical's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SEQUA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate SEQUA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SEQUA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SEQUA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SEQUA's dividend in 3 years as they are not forecast to pay a notable one for the Belgian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.8yrs

Average board tenure


CEO

Ian Crosbie

no data

Tenure

Mr. Ian Crosbie is the Chief Executive Officer of Sequana Medical NV. Mr. Crosbie has been the Chief Executive Officer of Sequana Medical AG since December 22, 2016. He served as Chief Financial Officer of ...


Board Members

NamePositionTenureCompensationOwnership
Ian Crosbie
CEO & Executive Directorno datano datano data
Erik Amble
Non-Executive Directorno datano datano data
Wim Ottevaere
Independent Non-Executive Director1.17yrsno datano data
Jason Hannon
Independent Non-Executive Director0.92yrno datano data
Rudy DeKeyser
Non-Executive Directorno datano datano data
Maria Costanzo
Scientific Advisor0.58yrno datano data
Pierre Chauvineau
Independent Chairman1.17yrsno datano data
Javed Butler
Scientific Advisor0.58yrno datano data
Jeffrey Testani
Scientific Advisor0.58yrno datano data
Wilson Tang
Scientific Advisor0.58yrno datano data

0.8yrs

Average Tenure

60yo

Average Age

Experienced Board: SEQUA's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 22.8%.


Top Shareholders

Company Information

Sequana Medical NV's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sequana Medical NV
  • Ticker: SEQUA
  • Exchange: ENXTBR
  • Founded: 2006
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €76.277m
  • Shares outstanding: 15.13m
  • Website: https://www.sequanamedical.com

Number of Employees


Location

  • Sequana Medical NV
  • AA Tower
  • Technologiepark 122
  • Ghent
  • East Flanders
  • 9052
  • Belgium

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SEQUAENXTBR (Euronext Brussels)YesOrdinary SharesBEEURFeb 2019
2SEBST (Boerse-Stuttgart)YesOrdinary SharesDEEURFeb 2019
SEQUABBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEURFeb 2019

Biography

Sequana Medical NV, a commercial stage medical device company, focuses on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites, and other fluid imbalance disorders. Its products include alfapump, a treatment solution for the long-term management of liver refractory ascites and malignant ascites; and alfapump DSR, a fully implanted system for direct sodium removal therapy in patients with volume overload due to heart failure. The company was founded in 2006 and is headquartered in Ghent, Belgium. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/04 06:10
End of Day Share Price2020/04/03 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.